BRPI0111222B8 - phosphonate derivatives of glycopeptide. - Google Patents

phosphonate derivatives of glycopeptide.

Info

Publication number
BRPI0111222B8
BRPI0111222B8 BRPI0111222A BR0111222A BRPI0111222B8 BR PI0111222 B8 BRPI0111222 B8 BR PI0111222B8 BR PI0111222 A BRPI0111222 A BR PI0111222A BR 0111222 A BR0111222 A BR 0111222A BR PI0111222 B8 BRPI0111222 B8 BR PI0111222B8
Authority
BR
Brazil
Prior art keywords
glycopeptide
derivatives
phosphonate derivatives
disclosed
phosphonate
Prior art date
Application number
BRPI0111222A
Other languages
Portuguese (pt)
Other versions
BRPI0111222B1 (en
BR0111222A (en
Inventor
S Linsell Martin
R Leadbeetter Michael
Original Assignee
Cumberland Pharmaceuticals Inc
Theravance Biopharma Antibiotics Ip Llc
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cumberland Pharmaceuticals Inc, Theravance Biopharma Antibiotics Ip Llc, Theravance Inc filed Critical Cumberland Pharmaceuticals Inc
Publication of BR0111222A publication Critical patent/BR0111222A/en
Publication of BRPI0111222B1 publication Critical patent/BRPI0111222B1/en
Publication of BRPI0111222B8 publication Critical patent/BRPI0111222B8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

"derivados fosfonados de glicopeptídeo". são revelados derivados de glicopeptídeos que são substituídos com um ou mais substituintes cada que compreendem um ou mais grupos fosfono; e composições farmacêuticas contendo tais derivados de glicopeptídeos. os derivados de glicopeptídeos revelados são úteis como agentes antibacterianos."phosphonate derivatives of glycopeptide". disclosed are glycopeptide derivatives which are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. the glycopeptide derivatives disclosed are useful as antibacterial agents.

BRPI0111222A 2000-06-22 2001-05-01 phosphonate derivatives of glycopeptide. BRPI0111222B8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21341000P 2000-06-22 2000-06-22
PCT/US2001/013998 WO2001098328A2 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Publications (3)

Publication Number Publication Date
BR0111222A BR0111222A (en) 2003-04-01
BRPI0111222B1 BRPI0111222B1 (en) 2015-03-17
BRPI0111222B8 true BRPI0111222B8 (en) 2021-05-25

Family

ID=22795013

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0111222A BRPI0111222B8 (en) 2000-06-22 2001-05-01 phosphonate derivatives of glycopeptide.

Country Status (36)

Country Link
US (10) US6635618B2 (en)
EP (1) EP1292612B1 (en)
JP (2) JP3900491B2 (en)
KR (1) KR100768488B1 (en)
CN (1) CN100469788C (en)
AR (1) AR035333A1 (en)
AT (1) ATE337334T1 (en)
AU (2) AU2001261107B2 (en)
BR (1) BRPI0111222B8 (en)
CA (2) CA2713965A1 (en)
CY (2) CY1105194T1 (en)
CZ (1) CZ303672B6 (en)
DE (2) DE60122516T2 (en)
DK (1) DK1292612T3 (en)
EA (1) EA005953B1 (en)
EG (1) EG26726A (en)
ES (1) ES2271012T3 (en)
HK (1) HK1052191B (en)
HR (1) HRP20020888B1 (en)
HU (2) HU229370B1 (en)
IL (1) IL152408A (en)
IS (1) IS2303B (en)
LU (1) LU91908I2 (en)
MX (1) MXPA02012745A (en)
MY (1) MY127081A (en)
NO (2) NO330360B1 (en)
NZ (1) NZ522279A (en)
PL (1) PL207101B1 (en)
PT (1) PT1292612E (en)
RS (1) RS50499B (en)
SI (1) SI1292612T1 (en)
SK (1) SK287470B6 (en)
TW (1) TWI305209B (en)
UA (1) UA75083C2 (en)
WO (1) WO2001098328A2 (en)
ZA (1) ZA200209419B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140093A0 (en) * 1998-12-23 2002-02-10 Advanced Medicine Inc Glycopeptide derivatives and pharmaceutical compositions containing the same
ATE416791T1 (en) 2000-05-02 2008-12-15 Theravance Inc COMPOSITION CONTAINING A CYCLODEXTRIN AND A GLYCOPEPTIDE ANTIBIOTIC
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
US6828299B2 (en) 2000-06-22 2004-12-07 Theravance, Inc. Polyhydroxy glycopeptide derivatives
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
UA75083C2 (en) * 2000-06-22 2006-03-15 Тераванс, Інк. Derivatives of glycopeptidephosphonates
US6620781B2 (en) 2000-06-22 2003-09-16 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
ES2384707T3 (en) * 2002-05-24 2012-07-11 Theravance, Inc. Cross-linked antibiotics of glycopeptides and cephalosporins
WO2003106399A2 (en) 2002-06-17 2003-12-24 Theravance, Inc. PROCESS FOR PREPARING N-PROTECTED β-AMINO ALDEHYDE COMPOUNDS
EP1641480A1 (en) * 2003-05-27 2006-04-05 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
WO2005018743A1 (en) * 2003-07-22 2005-03-03 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
WO2007082206A2 (en) * 2006-01-10 2007-07-19 Yu Ruey J N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
JP2008112847A (en) * 2006-10-30 2008-05-15 Shin Etsu Chem Co Ltd Process for manufacturing single crystal silicon solar cell and single crystal silicon solar cell
WO2008077241A1 (en) 2006-12-22 2008-07-03 Targanta Therapeutics, Inc. Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
US20090069219A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched telavancin
US8741966B2 (en) 2007-11-09 2014-06-03 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
CN101959849A (en) * 2007-12-26 2011-01-26 利德治疗公司 Novel semi-synthetic glycopeptides as antibacterial agents
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
US20100105607A1 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
EP2424559B1 (en) 2009-04-28 2024-04-03 Melinta Therapeutics, LLC Methods of treating bacterial infections using oritavancin
EA021177B1 (en) 2009-05-08 2015-04-30 Пронова Биофарма Норге Ас Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US20110009596A1 (en) * 2009-07-09 2011-01-13 Plus Chemicals Sa Process for the preparation of n-protected-decylaminoethanal
NZ610705A (en) 2010-11-05 2014-10-31 Pronova Biopharma Norge As Methods of treatment using lipid compounds
EP2753637A1 (en) 2011-09-09 2014-07-16 Sandoz AG Process for the synthesis of telavancin, its pharmaceutically acceptable salts as well as an n-protected imine-derivative of telavancin
EP2753638A1 (en) 2011-09-09 2014-07-16 Sandoz AG Process for the synthesis of telavancin and its pharmaceutically acceptable salts as well as n-protected derivatives thereof
JP5724937B2 (en) * 2012-04-23 2015-05-27 ニプロ株式会社 Peptides and preparations that show kidney accumulation
CN103897040B (en) * 2012-12-27 2018-05-22 浙江医药股份有限公司新昌制药厂 Novel glycopeptide class compound or pharmaceutically acceptable salt thereof and preparation method thereof and pharmaceutical composition and purposes
EP2961384B1 (en) 2013-02-28 2019-08-28 Basf As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CN105085636B (en) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 Vancomycin derivatives, preparation method thereof and application thereof in antibiosis
JP2018505910A (en) 2015-02-23 2018-03-01 セラヴァンス バイオファーマ アンチバイオティクス アイピー， エルエルシー Doses and methods for administering telavancin
US20180104201A1 (en) 2015-04-28 2018-04-19 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis
CN106188243B (en) * 2015-05-05 2020-06-26 博瑞生物医药（苏州）股份有限公司 Preparation method of oritavancin
US20200171124A1 (en) 2016-04-15 2020-06-04 Lupin Limited Topical compositions for ophthalmic and otic use
BR112018072948A2 (en) * 2016-05-09 2019-02-19 Xellia Pharmaceuticals Aps liquid pharmaceutical composition; and, method for stabilizing a glycopeptide antibiotic in a liquid pharmaceutical solution.
CA3062567A1 (en) 2017-05-22 2018-11-29 Insmed Incorporated Glycopeptide derivative compounds and uses thereof
CN107629115B (en) * 2017-09-08 2021-05-07 福建省微生物研究所 Purification method of telavancin
CN107629116B (en) * 2017-09-08 2021-05-07 福建省微生物研究所 Purification method of telavancin
CN107987131B (en) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 Compound with anti-drug-resistance bacterial activity, preparation method and application thereof
SG11202005007VA (en) 2017-12-06 2020-06-29 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN108409837B (en) 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 Glycopeptide compound with anti-drug resistance bacterial activity, preparation method and application thereof
JP2022507357A (en) * 2018-11-21 2022-01-18 インスメッド インコーポレイテッド Lipoglycopeptide cree bubble derivatives and their use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872A (en) * 1849-11-13 Means of changing the combination in bevolving tumbler-locks
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA2031803C (en) 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
AU672862B2 (en) 1992-12-02 1996-10-17 Insite Vision Incorporated Cyclodextrin and polymer based drug delivery system
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
RU2145609C1 (en) * 1994-01-28 2000-02-20 Эли Лилли Энд Компани Derivatives of glycopeptide or their salts, method of synthesis, pharmaceutical composition
US5614615A (en) 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
US6391851B1 (en) * 1997-03-10 2002-05-21 Fujisawa Pharmaceutical Co., Ltd. Hydrochlorides of vancomycin antibiotics and process for producing the same
US5916873A (en) 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
JP2002520422A (en) * 1998-07-14 2002-07-09 プリンストン ユニバーシティ Glycopeptide antibiotics, combinatorial library of glycopeptide antibiotics and method for producing the same
IL140093A0 (en) * 1998-12-23 2002-02-10 Advanced Medicine Inc Glycopeptide derivatives and pharmaceutical compositions containing the same
DE19911097A1 (en) 1999-03-12 2000-09-14 Basf Ag Process for the preparation of solid dosage forms containing cyclodextrin
US6518243B1 (en) 1999-04-02 2003-02-11 Trustees Of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
JP2000302687A (en) 1999-04-22 2000-10-31 Sagami Chem Res Center Antibacterial oligomer and antibacterial agent
ATE416791T1 (en) 2000-05-02 2008-12-15 Theravance Inc COMPOSITION CONTAINING A CYCLODEXTRIN AND A GLYCOPEPTIDE ANTIBIOTIC
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
KR20080056308A (en) 2000-06-21 2008-06-20 큐비스트 파마슈티컬즈 인코포레이티드 Compositions and methods to improve the oral absorption of antimicrobial agents
US6620781B2 (en) 2000-06-22 2003-09-16 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
US6828299B2 (en) 2000-06-22 2004-12-07 Theravance, Inc. Polyhydroxy glycopeptide derivatives
UA75083C2 (en) * 2000-06-22 2006-03-15 Тераванс, Інк. Derivatives of glycopeptidephosphonates
WO2001098326A2 (en) 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives

Also Published As

Publication number Publication date
PL359419A1 (en) 2004-08-23
BRPI0111222B1 (en) 2015-03-17
EG26726A (en) 2014-06-18
ZA200209419B (en) 2004-02-19
US7351691B2 (en) 2008-04-01
IS6600A (en) 2002-10-29
WO2001098328A3 (en) 2002-04-11
PT1292612E (en) 2006-12-29
US7008923B2 (en) 2006-03-07
PL207101B1 (en) 2010-11-30
US20060063706A1 (en) 2006-03-23
IL152408A (en) 2009-05-04
US7700550B2 (en) 2010-04-20
US20050164916A1 (en) 2005-07-28
CZ303672B6 (en) 2013-02-20
CY1105194T1 (en) 2010-03-03
US20020022590A1 (en) 2002-02-21
US20040063916A1 (en) 2004-04-01
ATE337334T1 (en) 2006-09-15
YU96902A (en) 2006-01-16
HRP20020888A2 (en) 2005-02-28
NO330360B1 (en) 2011-04-04
JP2007045842A (en) 2007-02-22
US6635618B2 (en) 2003-10-21
US8541375B2 (en) 2013-09-24
NO2011025I1 (en) 2011-11-18
CA2411590A1 (en) 2001-12-27
NO20025954L (en) 2002-12-11
AU6110701A (en) 2002-01-02
US7208471B2 (en) 2007-04-24
AR035333A1 (en) 2004-05-12
US20140024604A1 (en) 2014-01-23
NZ522279A (en) 2004-07-30
RS50499B (en) 2010-03-02
JP2004501161A (en) 2004-01-15
EA005953B1 (en) 2005-08-25
CY2012006I1 (en) 2016-06-22
DK1292612T3 (en) 2007-01-02
MXPA02012745A (en) 2004-04-05
DE122011100062I1 (en) 2012-03-15
JP3900491B2 (en) 2007-04-04
TWI305209B (en) 2009-01-11
KR20030032970A (en) 2003-04-26
IS2303B (en) 2007-10-15
SK287470B6 (en) 2010-10-07
US6872701B2 (en) 2005-03-29
US20100160211A1 (en) 2010-06-24
CA2713965A1 (en) 2001-12-27
LU91908I2 (en) 2012-01-30
BR0111222A (en) 2003-04-01
CZ20023942A3 (en) 2003-03-12
HU229370B1 (en) 2013-11-28
AU2001261107B2 (en) 2006-07-20
US8859506B2 (en) 2014-10-14
HK1052191B (en) 2007-01-26
CN1437611A (en) 2003-08-20
EA200300050A1 (en) 2003-04-24
DE60122516D1 (en) 2006-10-05
NO2011025I2 (en) 2011-11-18
SK18522002A3 (en) 2003-06-03
UA75083C2 (en) 2006-03-15
ES2271012T3 (en) 2007-04-16
US8101575B2 (en) 2012-01-24
HUS1400024I1 (en) 2017-03-28
WO2001098328A2 (en) 2001-12-27
DE60122516T2 (en) 2007-01-04
MY127081A (en) 2006-11-30
US20070049519A1 (en) 2007-03-01
HUP0301320A3 (en) 2007-05-29
US20030207797A1 (en) 2003-11-06
CN100469788C (en) 2009-03-18
IL152408A0 (en) 2003-05-29
NO20025954D0 (en) 2002-12-11
CA2411590C (en) 2010-10-19
EP1292612B1 (en) 2006-08-23
US6887976B2 (en) 2005-05-03
SI1292612T1 (en) 2006-12-31
CY2012006I2 (en) 2016-06-22
HK1052191A1 (en) 2003-09-05
KR100768488B1 (en) 2007-10-18
EP1292612A2 (en) 2003-03-19
US20120283195A1 (en) 2012-11-08
HRP20020888B1 (en) 2007-12-31
US20080312407A1 (en) 2008-12-18
HUP0301320A2 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
BRPI0111222B8 (en) phosphonate derivatives of glycopeptide.
BR9914221B1 (en) GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
BR0116452A (en) Compound, pharmaceutical composition, use of a compound
CO4930259A1 (en) DERIVATIVES 6,6-HETEROBICICLICOS SUBSTITUTED AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
TR200101499T1 (en) Azepinoindole derivatives, their preparation and uses.
BR0112030A (en) New compounds that have antibacterial, antifungal or antitumor activity
DK0960107T3 (en) 6-Thiosubstituted paclitaxels
MEP36908A (en) omega-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
ATE231872T1 (en) THIAZOLOPYRIMIDE DERIVATIVES
NO20021859D0 (en) New digosaccharides, their preparation as well as pharmaceutical preparations
ECSP034442A (en) MIXTURES OF POLYACARIDS DERIVED FROM HEPARINE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR021843A1 (en) DERIVATIVES OF PROPANOLAMINE SUBSTITUTED WITH HETEROCICLES, PROCEDURE FOR THEIR PREPARATION, AND ITS USE.
AR020563A1 (en) TIA-ALQUINOIC COMPOUNDS (POLI) AND THEIR DERIVATIVES, COMPOSITIONS THAT INCLUDE THEM AND THEIR USE
SE9801494D0 (en) Novel use
ATE388960T1 (en) GLYCOPEPTIDE DERIVATIVES WITH CARBOXY SACCHARIDES
EP1073447A4 (en) N1-modified glycopeptides
ATE305517T1 (en) NEUROTRYPSIN
NO20020914D0 (en) Alkoxy-substituted benzimidazole compounds, preparations containing them and their applications
DK1011329T3 (en) 7-Methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels
TR200103169T2 (en) 1,5-Benzodiazepine derivatives
PT1140932E (en) 1,8-BENZONETHYRIDINE DERIVATIVES
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents
SV2002000210A (en) HYGROMYCIN PROPHARMS A REF. PC10548AJNM / BB

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/03/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/05/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/05/2021